同位素2026，Vol.39Issue(3)：292-296,5.DOI:10.7538/tws.2025.youxian.062
中国放射性同位素进展(2016-2025年)
Domestic Developments in Isotope Technology(2016-2025)
张利峰 1吴志芳 2罗志福 1杜进 3魏洪源 4张劲松 5张锦明 6张岚 7秦芝 8褚泰伟9
作者信息
- 1. 中国原子能科学研究院,北京 102413||国家同位素工程技术研究中心,北京 102413
- 2. 清华大学,北京 100084
- 3. 中国同辐股份有限公司,北京 100089
- 4. 中国工程物理研究院核物理与化学研究所,绵阳 621900
- 5. 中国核动力研究设计院,成都 610213
- 6. 中国人民解放军总医院,北京 100853
- 7. 中国科学院上海应用物理研究所,上海 201800
- 8. 中国科学院近代物理研究所,兰州 730000
- 9. 北京大学,北京 100871
- 折叠
摘要
Abstract
The past decade(2016-2025)marks a strategic transition period for China's isotope technology to transform from reliance on imports to independent innovation.To systematically analyze the breakthroughs and existing challenges in this field,this paper examines seven key areas over the past decade:national policy planning,production facility construction,research and development of core technologies,market entry of isotope products,radioactive source applications,radiopharmaceuticals,industrial park layout,and R&D platform construction.It integrates policy documents,technical reports,and industrial data,conducts a comprehensive review and summary,and analyzes existing issues and shortcomings.Suggestions for subsequent development have been proposed in response to the identified issue.关键词
同位素技术/放射性药物Key words
isotope technology/radiopharmaceuticals分类
能源科技引用本文复制引用
张利峰,吴志芳,罗志福,杜进,魏洪源,张劲松,张锦明,张岚,秦芝,褚泰伟..中国放射性同位素进展(2016-2025年)[J].同位素,2026,39(3):292-296,5.
